



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Rua Bioscience Limited (Rua)
23-Oct-25
20-Aug-25

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Teresa Farac-Ciprian
Rua Bioscience
N/A
Director

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

Ordinary shares
Shareholder

For that relevant interest-

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

525,000
525,000
N/A - new issue of warrants for possible conversion to shares
Teresa Farac-Ciprian

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

Warrants
Ordinary Shares

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):

162,145 warrants. This issue of warrants represents 0.072% of the total ordinary shares on issue (being the percentage should all warrants vest and be exercised). At \$0.015 warrant price is \$2432.18
No consideration is payable for the warrants. Cash consideration of \$0.015 per share is payable on exercise of the warrants
5/06/2028
5/06/2028
\$0.015

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

N/A

For that derivative,-

Parties to the derivative:

Teresa Farac-Ciprian

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

1

Details of transactions requiring disclosure-

Date of transaction:

6-Jun-25

Nature of transaction:

Issue of warrants as part of a Debt Facility arrangement announced 13 May 2025.

Name of any other party or parties to the transaction (if known):

Rua Bioscience Limited

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

No consideration is payable for the warrants. Cash consideration of \$0.015 per share is payable on exercise of the warrants

Number of financial products to which the transaction related:

162,145

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

N/A

Date of the prior written clearance (if any):

N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Ordinary Shares

Nature of relevant interest:

Registered holder

For that relevant interest,-

Number held in class:

525,000 ordinary shares

Current registered holder(s):

Teresa Farac-Ciprian

For a derivative relevant interest,-

Type of derivative:

301,925 warrants

Details of derivative

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

162,145 warrants. This issue of warrants represents 0.073% of the total ordinary shares on issue

A statement as to whether the derivative is cash settled or physically settled:

No consideration is payable for the warrants. Cash consideration of \$0.015 per share is payable on exercise of the warrants

Maturity date of the derivative (if any):

5/06/2028

Expiry date of the derivative (if any):

5/06/2028

The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative relevant interest,-</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

\$0.015
N/A
Teresa Farac-Ciprian
N/A

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:



23/10/2025

Paul Naske, CEO